Niclosamide blocks glucagon phosphorylation of Ser552 on β-catenin in primary rat hepatocytes via PKA signalling

Biochemical Journal

Volumn 473, Issue 9, 2016, Pages 1247-1255

  Chowdhury, Md Kamrul H ^a   Wu, Lindsay E ^a   Coleman, James L J ^b   Smith, Nicola J ^b   Morris, Margaret J ^a   Shepherd, Peter R ^c   Smith, Greg C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Glucagon; H89; Niclosamide; Protein kinase A (pka); Type 2 diabetes.; catenin

Indexed keywords

ADRENALIN; BETA CATENIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; GLUCAGON; INSULIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NICLOSAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; WNT PROTEIN; BUCLADESINE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; INCUBATION TIME; LIVER CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; BETA CATENIN; BUCLADESINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS, TYPE 2; GLUCAGON; HEPATOCYTES; MALE; NICLOSAMIDE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84975149912     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BCJ20160121     Document Type: Article

References (57)

1. Boyle, J.P., Thompson, T.J., Gregg, E.W., Barker, L.E. and Williamson, D.F. (2010) Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 8,29 CrossRef PubMed
2. International Diabetes Federation (2013), IDF Diabetes Atlas, International Diabetes Federation, Brussels
3. Joshi, S., Liu, M. and Turner, N. (2015) Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime. Biomed. Res. Int. 2015, 390863 CrossRef PubMed
4. Kahn, S.E., Cooper, M.E. and Del Prato, S. (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068-1083CrossRef PubMed
5. Consoli, A. (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care 15, 430-441 CrossRef PubMed
6. Dinneen, S., Alzaid, A., Turk, D. and Rizza, R. (1995) Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38, 337-343 CrossRef PubMed
7. Baron, A.D., Schaeffer, L., Shragg, P. and Kolterman, O.G. (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36, 274-283 CrossRef PubMed
8. Unger, R.H., Aguilar-Parada, E., Muller, W.A. and Eisentraut, A.M. (1970) Studies of pancreatic α cell function in normal and diabetic subjects. J. Clin. Invest. 49, 837-848 CrossRef PubMed
9. Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thevenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W.J. et al. (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic α cells triggers glucagon secretion. Nat. Med. 21, 512-517 CrossRef PubMed
10. Chowdhury, M.K., Montgomery, M.K., Morris, M.J., Cognard, E., Shepherd, P.R. and Smith, G.C. (2015) Glucagon phosphorylates serine 552 of β-catenin leading to increased expression of cyclin D1 and c-Myc in the isolated rat liver. Arch. Physiol. Biochem. 121, 88-96 CrossRef PubMed
11. Wang, C., Wang, X., Gong, G., Ben, Q., Qiu, W., Chen, Y., Li, G. and Wang, L. (2012) Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int. J. Cancer 130, 1639-1648 CrossRef PubMed
12. Xu, C.X., Zhu, H.H. and Zhu, Y.M. (2014) Diabetes and cancer: associations, mechanisms, and implications for medical practice. World J. Diabetes 5, 372-380 CrossRef PubMed
13. Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., Pollak, M., Regensteiner, J.G. and Yee, D. (2010) Diabetes and cancer: a consensus report. CA Cancer J. Clin. 60, 207-221 CrossRef PubMed
14. Chien, A.J., Conrad, W.H. and Moon, R.T. (2009) A Wnt survival guide: from flies to human disease. J. Invest. Dermatol. 129, 1614-1627 CrossRef PubMed
15. de La Coste, A., Romagnolo, B., Billuart, P., Renard, C.A., Buendia, M.A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A. and Perret, C. (1998) Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U.S.A. 95, 8847-8851 CrossRef PubMed
16. Miyoshi, Y., Iwao, K., Nagasawa, Y., Aihara, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T. and Nakamura, Y. (1998) Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58, 2524-2527 PubMed
17. Lin, C.P., Liu, C.R., Lee, C.N., Chan, T.S. and Liu, H.E. (2010) Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J. Hepatol. 2, 16-20 PubMed
18. Zhang, Y.J., Jiang, W., Chen, C.J., Lee, C.S., Kahn, S.M., Santella, R.M. and Weinstein, I.B. (1993) Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 196, 1010-1016 CrossRef PubMed
19. Dang, C.V. (2012) MYC on the path to cancer. Cell 149, 22-35 CrossRef PubMed
20. He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, P.J., Vogelstein, B. and Kinzler, K.W. (1998) Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512 CrossRef PubMed
21. Alao, J.P. (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 24CrossRef PubMed
22. Miller, D.M., Thomas, S.D., Islam, A., Muench, D. and Sedoris, K. (2012) c-Myc and cancer metabolism. Clin. Cancer Res. 18, 5546-5553 CrossRef PubMed
23. White, B.D., Chien, A.J. and Dawson, D.W. (2012) Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 142, 219-232 CrossRef PubMed
24. Gotoh, J., Obata, M., Yoshie, M., Kasai, S. and Ogawa, K. (2003) Cyclin D1 over-expression correlates with β-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3β and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 24, 435-442 CrossRef PubMed
25. Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., Ikenaga, M. et al. (1994) Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54, 3107-3110 PubMed
26. Adami, H.O., Chow, W.H., Nyren, O., Berne, C., Linet, M.S., Ekbom, A., Wolk, A., McLaughlin, J.K. and Fraumeni, Jr, J.F. (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl. Cancer Inst. 88, 1472-1477 CrossRef PubMed
27. La Vecchia, C., Negri, E., Decarli, A. and Franceschi, S. (1997) Diabetes mellitus and the risk of primary liver cancer. Int. J. Cancer 73, 204-207 CrossRef PubMed
28. Nelson, R., Persky, V., Davis, F. and Becker, E. (1997) Re: Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl. Cancer Inst. 89, 327-328 CrossRef PubMed
29. Yang, W.S., Shu, X.O., Gao, J., Li, H.L., Cai, H., Yang, G., Ji, B.T., Rothman, N., Gao, Y.T., Zheng, W. and Xiang, Y.B. (2013) Prospective evaluation of type 2 diabetes mellitus on the risk of primary liver cancer in Chinese men and women. Ann. Oncol. 24, 1679-1685 CrossRef PubMed
30. Tao, H., Zhang, Y., Zeng, X., Shulman, G.I. and Jin, S. (2014) Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat. Med. 20, 1263-1269 CrossRef PubMed
31. Maira, S.M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chene, P., De Pover, A., Schoemaker, K. et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 CrossRef PubMed
32. Jamieson, S., Flanagan, J.U., Kolekar, S., Buchanan, C., Kendall, J.D., Lee, W.J., Rewcastle, G.W., Denny, W.A., Singh, R., Dickson, J. et al. (2011) A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem. J. 438, 53-62 CrossRef PubMed
33. Jackson, S.P., Schoenwaelder, S.M., Goncalves, I., Nesbitt, W.S., Yap, C.L., Wright, C.E., Kenche, V., Anderson, K.E., Dopheide, S.M., Yuan, Y. et al. (2005) PI 3-kinase p110β:a new target for antithrombotic therapy. Nat. Med. 11, 507-514 CrossRef PubMed
34. Sadhu, C., Masinovsky, B., Dick, K., Sowell, C.G. and Staunton, D.E. (2003) Essential role of phosphoinositide 3-kinase ä in neutrophil directional movement. J. Immunol. 170, 2647-2654 CrossRef PubMed
35. Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2- ôôCT method. Methods 25, 402-408 CrossRef PubMed
36. Pfaffl, M.W., Horgan, G.W. and Dempfle, L. (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30, e36CrossRef PubMed
37. Gemmell, M.A., Johnstone, P.D. and Oudemans, G. (1977) The effect of niclosamide on Echinococcus granulosus, Taenia hydatigena and Taenia ovis infections in dogs. Res. Vet. Sci. 22, 389-391 PubMed
38. Pearson, R.D. and Hewlett, E.L. (1985) Niclosamide therapy for tapeworm infections. Ann. Intern. Med. 102, 550-551 CrossRef PubMed
39. Chen, M., Wang, J., Lu, J., Bond, M.C., Ren, X.R., Lyerly, H.K., Barak, L.S. and Chen, W. (2009) The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 48, 10267-10274 CrossRef PubMed
40. Osada, T., Chen, M., Yang, X.Y., Spasojevic, I., Vandeusen, J.B., Hsu, D., Clary, B.M., Clay, T.M., Chen, W., Morse, M.A. and Lyerly, H.K. (2011) Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 71, 4172-4182 CrossRef PubMed
41. Ono, M., Yin, P., Navarro, A., Moravek, M.B., Coon, V.J., Druschitz, S.A., Gottardi, C.J. and Bulun, S.E. (2014) Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth. Fertil. Steril. 101, 1441-1449 CrossRef PubMed
42. Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Hofer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L. et al. (2013) Anticancer effects of niclosamide in human glioblastoma. Clin. Cancer Res. 19, 4124-4136 CrossRef PubMed
43. Kundu, J.K., Surh and -J., Y. (2008) Inflammation: gearing the journey to cancer. Mutat. Res. 659, 15-30 CrossRef PubMed
44. Arcidiacono, B., Iiritano, S., Nocera, A., Possidente, K., Nevolo, M.T., Ventura, V., Foti, D., Chiefari, E. and Brunetti, A. (2012) Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp. Diabetes Res. 2012, CrossRef
45. Balkau, B., Kahn, H.S., Courbon, D., Eschwège, E. and Ducimetière, P. (2001) Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care 24, 843-849 CrossRef PubMed
46. Giovannucci, E. (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr. 131 Suppl., 3109S-3120S PubMed
47. García-Jiménez, C., García-Martínez, J.M., Chocarro-Calvo, A. and De la Vieja, A. (2014) A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose. J. Mol. Endocrinol. 52, R51-R66 PubMed
48. Birnbaum, M.J. and Fain, J.N. (1977) Activation of protein kinase and glycogen phosphorylase in isolated rat liver cells by glucagon and catecholamines. J. Biol. Chem. 252, 528-535 PubMed
49. Cavard, C., Colnot, S., Audard, V., Benhamouche, S., Finzi, L., Torre, C., Grimber, G., Godard, C., Terris, B. and Perret, C. (2008) Wnt/β-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 4, 647-660 CrossRef PubMed
50. Zender, L., Villanueva, A., Tovar, V., Sia, D., Chiang, D.Y. and Llovet, J.M. (2010) Cancer gene discovery in hepatocellular carcinoma. J. Hepatol. 52, 921-929 CrossRef PubMed
51. Emmanuelle, C., Coralie, G.D., Deborah, L.H. and Peter, R.S. (2013) Identification of a pathway by which glucose regulates β-catenin signalling via the cAMP/protein kinase A pathway in β-cell models. Biochem. J. 449, 803-811 CrossRef PubMed
52. Taurin, S., Sandbo, N., Qin, Y., Browning, D. and Dulin, N.O. (2006) Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase. J. Biol. Chem. 281, 9971-9976 CrossRef PubMed
53. Leemhuis, J., Boutillier, S., Schmidt, G. and Meyer, D.K. (2002) The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J. Pharmacol. Exp. Ther. 300, 1000-1007 CrossRef PubMed
54. Lochner, A. and Moolman, J.A. (2006) The many faces of H89: a review. Cardiovasc. Drug Rev. 24, 261-274 CrossRef PubMed
55. Owen, M.R., Doran, E. and Halestrap, A.P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607-614 CrossRef PubMed
56. Pernicova, I. and Korbonits, M. (2014) Metformin: mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10, 143-156 CrossRef PubMed
57. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 CrossRef PubMed